PE20170523A1 - Formulacion en forma de tableta de 2-fluor-n-metil-4-[7-(quinolin-6-ylmetil)imidazo[1,2- b][1,2,4]triazin-2-il]benzamida - Google Patents

Formulacion en forma de tableta de 2-fluor-n-metil-4-[7-(quinolin-6-ylmetil)imidazo[1,2- b][1,2,4]triazin-2-il]benzamida

Info

Publication number
PE20170523A1
PE20170523A1 PE2017000097A PE2017000097A PE20170523A1 PE 20170523 A1 PE20170523 A1 PE 20170523A1 PE 2017000097 A PE2017000097 A PE 2017000097A PE 2017000097 A PE2017000097 A PE 2017000097A PE 20170523 A1 PE20170523 A1 PE 20170523A1
Authority
PE
Peru
Prior art keywords
triazin
quinolin
imidazo
benzamide
ylmethyl
Prior art date
Application number
PE2017000097A
Other languages
English (en)
Spanish (es)
Inventor
Elisabete Goncalves
Christin Tauchmann
Shau-Fong Yen
Sudha Vippagunta
Zhixin Zong
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=53762251&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20170523(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of PE20170523A1 publication Critical patent/PE20170523A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J3/00—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms
    • A61J3/10—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms into the form of compressed tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J3/00—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms
    • A61J3/06—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms into the form of pills, lozenges or dragees
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
PE2017000097A 2014-07-25 2015-07-22 Formulacion en forma de tableta de 2-fluor-n-metil-4-[7-(quinolin-6-ylmetil)imidazo[1,2- b][1,2,4]triazin-2-il]benzamida PE20170523A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201462028865P 2014-07-25 2014-07-25

Publications (1)

Publication Number Publication Date
PE20170523A1 true PE20170523A1 (es) 2017-05-17

Family

ID=53762251

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2017000097A PE20170523A1 (es) 2014-07-25 2015-07-22 Formulacion en forma de tableta de 2-fluor-n-metil-4-[7-(quinolin-6-ylmetil)imidazo[1,2- b][1,2,4]triazin-2-il]benzamida

Country Status (31)

Country Link
US (5) US10085993B2 (enExample)
EP (2) EP3172209B1 (enExample)
JP (3) JP6770946B2 (enExample)
KR (2) KR102581121B1 (enExample)
CN (2) CN106714784A (enExample)
AR (1) AR101286A1 (enExample)
AU (4) AU2015293539A1 (enExample)
CA (1) CA2954840A1 (enExample)
CL (1) CL2017000180A1 (enExample)
CO (1) CO2017000586A2 (enExample)
DK (1) DK3172209T3 (enExample)
EA (2) EA039220B1 (enExample)
EC (1) ECSP17011672A (enExample)
ES (1) ES2857523T3 (enExample)
FR (1) FR22C1058I2 (enExample)
GT (1) GT201700007A (enExample)
HU (2) HUE053346T2 (enExample)
IL (1) IL250166B (enExample)
JO (1) JO3618B1 (enExample)
MX (2) MX379279B (enExample)
MY (1) MY187276A (enExample)
NL (1) NL301208I2 (enExample)
NO (1) NO2022058I1 (enExample)
PE (1) PE20170523A1 (enExample)
PH (1) PH12017500121A1 (enExample)
PL (1) PL3172209T3 (enExample)
PT (1) PT3172209T (enExample)
SG (2) SG10201900648SA (enExample)
SI (1) SI3172209T1 (enExample)
TW (2) TW202200148A (enExample)
WO (1) WO2016012963A1 (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2894830T3 (es) 2012-04-03 2022-02-16 Novartis Ag Productos combinados con inhibidores de tirosina·cinasa y su uso
DK3172209T3 (da) 2014-07-25 2021-02-22 Novartis Ag Tabletformulering med 2-fluor-n-methyl-4-[7-(quinolin-6-ylmethyl)imidazo[1,2-b][1,2,4]triazin-2-yl]benzamid
PL3496722T3 (pl) 2016-08-10 2025-11-12 F. Hoffmann-La Roche Ag Kompozycje farmaceutyczne zawierające inhibitory kinazy białkowej Akt
TWI853027B (zh) 2019-05-16 2024-08-21 瑞士商諾華公司 N-[4-(氯二氟甲氧基)苯基]-6-[(3r)-3-羥基吡咯啶-1-基]-5-(1h-吡唑-5-基)吡啶-3-甲醯胺之結晶形狀
CN114502144A (zh) * 2019-10-24 2022-05-13 韩美药品株式会社 包含抑制癌细胞生长的酰胺衍生物的药物制剂以及包含其的药物产品
WO2022007752A1 (zh) * 2020-07-06 2022-01-13 苏州晶云药物科技股份有限公司 苯甲酰胺类化合物及其二盐酸盐的新晶型及其制备方法
CN114853762A (zh) * 2021-02-03 2022-08-05 四川科伦药物研究院有限公司 一种咪唑并三嗪类化合物的固体形式及其制备方法和用途
CN118251220A (zh) * 2022-01-19 2024-06-25 江苏奥赛康药业有限公司 一种包含嘧啶基团的三并环类化合物的组合物及其制备方法和应用
WO2023249994A1 (en) * 2022-06-22 2023-12-28 Mayo Foundation For Medical Education And Research Methods and materials for treating cancer
KR20250042846A (ko) 2022-08-19 2025-03-27 미라티 테라퓨틱스, 인크. 아다그라십 고체 제약 조성물
KR20250164828A (ko) 2023-03-30 2025-11-25 레볼루션 메디슨즈, 인크. Ras gtp 가수분해 유도를 위한 조성물 및 이의 용도
AU2024265078A1 (en) 2023-05-04 2025-12-11 Revolution Medicines, Inc. Combination therapy for a ras related disease or disorder
WO2025034702A1 (en) 2023-08-07 2025-02-13 Revolution Medicines, Inc. Rmc-6291 for use in the treatment of ras protein-related disease or disorder
WO2025080946A2 (en) 2023-10-12 2025-04-17 Revolution Medicines, Inc. Ras inhibitors
WO2025171296A1 (en) 2024-02-09 2025-08-14 Revolution Medicines, Inc. Ras inhibitors
WO2025240847A1 (en) 2024-05-17 2025-11-20 Revolution Medicines, Inc. Ras inhibitors
WO2025255438A1 (en) 2024-06-07 2025-12-11 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6762778B1 (en) 1999-06-10 2004-07-13 Dassault Systemes Three dimensional graphical manipulator
CA2465565A1 (en) * 2003-06-12 2004-12-12 Warner-Lambert Company Llc Pharmaceutical compositions of atorvastatin
CA2615063A1 (en) * 2005-07-22 2007-02-01 Myriad Genetics, Inc. High drug load formulations and dosage forms
KR101313395B1 (ko) 2005-09-12 2013-10-02 액테리온 파마슈티칼 리미티드 피리미딘-설파마이드를 함유하는 안정한 제약학적 조성물
CA2563690C (en) 2006-10-12 2014-10-07 Pharmascience Inc. Pharmaceutical compositions comprising intra- and extra- granular fractions
EP2497470B8 (en) 2006-11-22 2015-12-02 Incyte Holdings Corporation Imidazotriazines and imidazopyrimidines as kinase inhibitors
NZ589622A (en) 2008-05-21 2012-10-26 Incyte Corp Salts of 2-fluoro-N-methyl-4-[7-(quinolin-6-yl-methyl)-imidazo[1,2-b][1,2,4]triazin-2-yl]benzamide and processes related to preparing the same
HUE071632T2 (hu) * 2009-11-09 2025-09-28 Wyeth Llc Neratinib-maleát tabletta készítmények
KR20210124532A (ko) 2010-02-25 2021-10-14 브리스톨-마이어스 스퀴브 홀딩스 아일랜드 언리미티드 컴퍼니 아픽사반 제제
EA202091303A3 (ru) * 2010-05-21 2021-05-31 Инсайт Холдингс Корпорейшн Композиция ингибитора jak для местного применения
EP2590631B1 (en) * 2010-07-06 2016-10-26 Janssen Pharmaceutica NV Formulation for co-therapy treatment of diabetes
KR20210049187A (ko) 2012-08-16 2021-05-04 노파르티스 아게 Pi3k 억제제와 c-met 억제제의 조합물
DK3172209T3 (da) 2014-07-25 2021-02-22 Novartis Ag Tabletformulering med 2-fluor-n-methyl-4-[7-(quinolin-6-ylmethyl)imidazo[1,2-b][1,2,4]triazin-2-yl]benzamid

Also Published As

Publication number Publication date
AU2020200912A1 (en) 2020-02-27
MX2017001177A (es) 2017-05-01
KR20170039211A (ko) 2017-04-10
PH12017500121A1 (en) 2017-05-29
EP3848376A1 (en) 2021-07-14
IL250166A0 (en) 2017-03-30
JO3618B1 (ar) 2020-08-27
SG11201700147SA (en) 2017-02-27
KR102581121B1 (ko) 2023-09-21
PT3172209T (pt) 2021-02-11
SG10201900648SA (en) 2019-02-27
EP3172209B1 (en) 2020-12-02
US20190015418A1 (en) 2019-01-17
IL250166B (en) 2021-01-31
CL2017000180A1 (es) 2017-09-15
NO2022058I1 (no) 2022-12-16
AU2015293539A1 (en) 2017-02-02
KR20230136693A (ko) 2023-09-26
JP6770946B2 (ja) 2020-10-21
EA202191301A1 (ru) 2021-11-30
ECSP17011672A (es) 2018-03-31
US12208101B2 (en) 2025-01-28
MX2021000595A (es) 2021-04-13
NZ728089A (en) 2024-01-26
US10085993B2 (en) 2018-10-02
HUS2200054I1 (hu) 2023-01-28
JP2020114852A (ja) 2020-07-30
TW201613595A (en) 2016-04-16
EA201790259A1 (ru) 2017-06-30
DK3172209T3 (da) 2021-02-22
EA039220B1 (ru) 2021-12-20
AU2021202500A1 (en) 2021-05-20
US20210113569A1 (en) 2021-04-22
AU2020200912B2 (en) 2021-01-28
CN106714784A (zh) 2017-05-24
US20220249498A1 (en) 2022-08-11
AR101286A1 (es) 2016-12-07
CA2954840A1 (en) 2016-01-28
BR112017000953A2 (pt) 2017-11-14
MX379279B (es) 2025-03-11
JP2022046659A (ja) 2022-03-23
MY187276A (en) 2021-09-17
AU2018207947A1 (en) 2018-08-09
EP3172209A1 (en) 2017-05-31
NL301208I2 (nl) 2025-03-20
GT201700007A (es) 2018-12-18
JP2017521469A (ja) 2017-08-03
TWI724993B (zh) 2021-04-21
TW202200148A (zh) 2022-01-01
WO2016012963A1 (en) 2016-01-28
HUE053346T2 (hu) 2021-06-28
JP7002587B2 (ja) 2022-01-20
US10596178B2 (en) 2020-03-24
CO2017000586A2 (es) 2017-06-20
PL3172209T3 (pl) 2021-06-14
SI3172209T1 (sl) 2021-03-31
US20170231997A1 (en) 2017-08-17
CN115364061A (zh) 2022-11-22
FR22C1058I1 (fr) 2023-01-06
US20250339440A1 (en) 2025-11-06
ES2857523T3 (es) 2021-09-29
FR22C1058I2 (fr) 2023-11-17

Similar Documents

Publication Publication Date Title
PE20170523A1 (es) Formulacion en forma de tableta de 2-fluor-n-metil-4-[7-(quinolin-6-ylmetil)imidazo[1,2- b][1,2,4]triazin-2-il]benzamida
CO2018013293A2 (es) Derivados de pirazolopirimidina como inhibidor de quinasa
DOP2014000200A (es) Compuestos inhibidores de raf
ECSP17029203A (es) Inhibidor de cinasa aurora a
PE20151654A1 (es) Inhibidores de cdc7
CL2017001426A1 (es) Nuevos compuestos de 5-amino-6h-tiazolo[4,5-d]pirimidin-2,7-diona 3-sustituidos para el tratamiento y profilaxis de infecciones virales.
AR108768A2 (es) Compuestos de piridina y pirazol y sus usos para la modulación de hemoglobina
CL2016002144A1 (es) Inhibidores de la jak1 para el tratamiento de síndromes mielodisplásicos.
CL2016000241A1 (es) Formulación de inhibidores de la syk.
AR098274A1 (es) Inhibidor de grelina o-acil transferasa
CL2015002897A1 (es) Inhibidores de bace1
SV2016005316A (es) Compuestos y composiciones para inducir condrogénesis
AR112144A1 (es) Compuestos para el tratamiento del sarcoma
CL2017002960A1 (es) Compuesto para la profilaxis o el tratamiento de daño al órgano
PH12017500159B1 (en) [1,2,4]triazolo[4,3-b]pyridazines for use in the treatment of proliferative diseases
TN2017000256A1 (en) Substituted pyridyl-cycloalkyl-carboxylic acids, compositions containing them and medical uses thereof
MX2017013103A (es) Metodos para el tratamiento de trastornos cardiovasculares.
DOP2019000194A (es) Derivados de pirrolotriazina como inhibidor de cinasas
UY36732A (es) Piridin pirazinonas novedosas como inhibidores de bromodominios de la familia bet
CR20150659A (es) Derivados de prodroga de triazolpiridinas sustituidas
GT201700227A (es) Derivados de aminohidrotiazina fusionados con tetrahidrofurano los cuales son utiles en el tratamiento de la enfermedad de alzheimer
MX2018001575A (es) Compuestos triciclicos y su uso en el tratamiento del cancer.
MX2018012587A (es) (+)-azasetron para uso en el tratamiento de trastornos del oido.
NI201700072A (es) Compuestos para tratar el cáncer.
CL2015001705A1 (es) Uso de pidotimod para tratar la psoriasis